Combination of cowpea mosaic virus (CPMV) intratumoral therapy and oxaliplatin chemotherapy.

ABSTRACT: Cowpea mosaic virus is a potent intratumoral immunotherapy agent that has shown promise in preclinical studies and canine cancer trials with tumor- and tissue-agnostic efficacy. As we move towards the clinic, it is imperative to investigate combination strategies that synergize to further improve the potency of the approach. Here, we combined CPMV with the clinically approved chemotherapeutic agent oxaliplatin. CPMV's ability to recruit and activate naive immune cells synergized with oxaliplatin's ability to induce immunogenic cell death in the ID8-Defb29/Vegf-A ovarian and B16F10 melanoma murine cancer models with an increase of median survival of 57.7% and 162.2%, respectively. The combination therapy outperformed the CPMV or oxaliplatin monotherapy, and achieved a percent difference in

SUBMITTER: Moreno-Gonzalez MA 

PROVIDER: S-EPMC11615731 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature